Biotech Values

[DewDiligence]

BMY—Historically these trials have enrolled much faster than expected. And I would suggest that that is because ifn-alpha is the primary toxic agent in current SOC and lambda is both substantially less toxic and substantially better efficacy than alpha.

But half the patients in this trial will be getting Pegasys (ifn-alpha).